Based on the Oric Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for Oric Pharmaceuticals Inc is USD 19.30 over the next 12 months. Oric Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Oric Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Oric Pharmaceuticals Inc’s stock price was USD 5.04. Oric Pharmaceuticals Inc’s stock price has changed by +18.45% over the past week, -35.30% over the past month and -46.67% over the last year.
No recent analyst target price found for Oric Pharmaceuticals Inc
No recent average analyst rating found for Oric Pharmaceuticals Inc
Company Overview Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read Less
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioava...Read More
Frequently Asked Questions About Oric Pharmaceuticals Inc (ORIC) Stock
Based on ratings from 6 analysts Oric Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on ORIC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ORIC is USD 19.30 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 13.
Unfortunately we do not have enough data on ORIC's stock to indicate if its overvalued.
The last closing price of ORIC's stock was USD 5.04.
The most recent market capitalization for ORIC is USD 0.35B.
Based on targets from 6 analysts, the average taret price for ORIC is projected at USD 19.30 over the next 12 months.
This means that ORIC's stock price may go up by +282.94% over the next 12 months.
We can't find any ETFs which contains Oric Pharmaceuticals Inc's stock.
As per our most recent records Oric Pharmaceuticals Inc has 115 Employees.
Oric Pharmaceuticals Inc's registered address is 240 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Oric Pharmaceuticals Inc's website at https://www.oricpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Oric Pharmaceuticals Inc (ORIC) Stock
Based on ratings from 6 analysts Oric Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on ORIC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ORIC is USD 19.30 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 13.
Unfortunately we do not have enough data on ORIC's stock to indicate if its overvalued.
The last closing price of ORIC's stock was USD 5.04.
The most recent market capitalization for ORIC is USD 0.35B.
Based on targets from 6 analysts, the average taret price for ORIC is projected at USD 19.30 over the next 12 months.
This means that ORIC's stock price may go up by +282.94% over the next 12 months.
We can't find any ETFs which contains Oric Pharmaceuticals Inc's stock.
As per our most recent records Oric Pharmaceuticals Inc has 115 Employees.
Oric Pharmaceuticals Inc's registered address is 240 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Oric Pharmaceuticals Inc's website at https://www.oricpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ORIC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
